Table 3 Patients’ characteristics according to response to infliximab, among the 54 patients eligible for efficacy assessment. CRP, C-reactive protein. Chi-square or Fisher’s exact and Mann-Whitney tests

Age, median (years, min-max)

47,5 [18–79]

44 [28–80]

1

Sex (men/women)

20/18 (53/47)

6/10 (37.5/62.5)

0.4

Ethnicity

Caucasian

Maghrebis

West-Indies

26 (69)

7 (18)

5 (13)

12 (75)

1 (6)

3 (19)

0.7

0.4

0.7

Median disease duration (months, IQR)

45 [13.5–98]

38,5 [17–100]

0.8

Main involved organ

Central nervous system

Lungs

Systemic disease

Liver

Eye

Peripheral nervous system

Muscles

Joints

Others

13 (34)

4 (10.5)

4 (10.5)

4 (10.5)

3 (8)

3 (8)

2 (5)

1 (3)

4 (10.5)

0

3 (19)

6 (37.5)

0

2 (12.5)

0

1 (6)

3 (19)

1 (6)

0.006

0.4

0.06

0.6

0.3

0.07

1

0.5

0.8

Lymphopenia

CD4⁺ count (×10⁹/L)

25 (69)

0.54

10 (67)

0.72

1

0.3

Increased gamma globulin levels

5 (18.5)

4 (36)

0.4

Inflammation with elevated CRP

19 (54)

6 (37.5)

0.4

Elevated angiotensin-converting enzyme

13 (37)

5 (36)

1

Median number of previous therapies (IQR)

2 [1–2.75]

2 [1–2.25]

0.7

Number of patients who required an increased doses of oral steroids

20 (53)

5 (31)

0.2

Median dose of oral steroids (mg/day, IQR)

17.5 [2.5–40]

20 [12–51]

0.3

Pulses of methylprednisolone

13 (34)

2 (12.5)

0.2

Concomitant immunosuppressant

8 (21)

3 (19)

1